Zydus gets USFDA approval to market Ivermectin cream

6 122
Representative image

DTMT Network

The United States Food and Drug Administration (USFDA) has given final approval to Zydus Lifesciences to market Ivermectin cream, 1%.

Ivermectin cream is used for the treatment of inflammatory lesions of rosacea.

The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad, India. Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).

The group now has 319 approvals and has so far filed over 420 ANDAs since the commencement of the filing process in FY 2003-04.


  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *


Drug Today Medical Times

Back to Top